Prediction of drug dissolution from Toremifene 80 mg tablets by NIR spectroscopy.

Design of experiments Discrimination capability Dissolution Near infrared spectroscopy PLS calibration model Toremifene

Journal

International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127

Informations de publication

Date de publication:
15 Mar 2020
Historique:
received: 09 09 2019
revised: 08 01 2020
accepted: 09 01 2020
pubmed: 20 1 2020
medline: 6 1 2021
entrez: 20 1 2020
Statut: ppublish

Résumé

The aim of our study was to justify substitution of dissolution analysis for NIR measurement of Toremifene 80 mg tablets. We studied implementation of a NIRS method by integrating the method development to discrimination power of the dissolution method. Hence, we analyzed 20 DoE tablet batches and studied which of the critical formulation factors affecting dissolution were statistically significant. To study if these factors can be detected by NIRS, PLS calibration models were developed. Finally, PLS model was built to correlate NIR data with the actual dissolution results to predict the released amount of toremifene in 30 min. To obtain the data the tablet batches were measured by NIR using diffuse reflectance technique and multivariate analysis tool was used to calibrate the NIRS models. Correlations between the critical formulation factors and the NIR spectra of Toremifene 80 mg tablet were shown and it was thus justified to develop a NIRS prediction model for dissolution. Variance (R

Identifiants

pubmed: 31954865
pii: S0378-5173(20)30010-7
doi: 10.1016/j.ijpharm.2020.119028
pii:
doi:

Substances chimiques

Tablets 0
Toremifene 7NFE54O27T

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

119028

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. KO, MM and AL are employees of Orion Pharma, Orion Corporation.

Auteurs

Krista Ojala (K)

Orion Pharma, P.O. Box 425, 20101 Turku, Finland. Electronic address: krista.ojala@orionpharma.com.

Mika Myrskyranta (M)

Orion Pharma, P.O. Box 425, 20101 Turku, Finland.

Anni Liimatainen (A)

Orion Pharma, P.O. Box 425, 20101 Turku, Finland.

Hanna Kortejärvi (H)

University of Helsinki, Finland.

Anne Juppo (A)

Division of Pharmaceutical Technology and Industrial Pharmacy, University of Helsinki, P.O. Box 56, 00014 University of Helsinki, Finland.

Articles similaires

Vancomycin Polyesters Anti-Bacterial Agents Models, Theoretical Drug Liberation
1.00
Iran Environmental Monitoring Seasons Ecosystem Forests
Cities China Government Conservation of Natural Resources Humans
Humans Female Prefrontal Cortex Male Spectroscopy, Near-Infrared

Classifications MeSH